Dianthus Therapeutics, Inc. /DE/ (DNTH) Financial Forecast
United States · Health Care · USD (Thousands) · Annual
Key financials
USD|Thousands
ROE
-38.38%
2025 (actual)
ROA
-35.88%
2025 (actual)
Gross Margin
100%
2025 (actual)
Net Margin
-
Total Assets
$530,922.00K
2025 (actual)
Net Income
-$162,337.00K
2025 (actual)
Valuation
$2,252,795.46K
2026 (forecast)
Stock Price
$41.21
Historical & projected performance
USD|Thousands
Reported figures and Equlion model projections for the next 5 years.
ROE
-865 pt
Company
Sector average (own scale)
ROA
+18.2 pt
Company
Gross Margin
+0 pt
Company
Sector average
Total Assets
+234.9%
Company
Sector average (own scale)
Net Income
-87.9%
Company
Valuation
+67.2%
Company
Sector average (own scale)
Stock Price
+67.2%
Company
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2026. Projections are model estimates, not investment advice.
Want the full financial forecast report for Dianthus Therapeutics, Inc. /DE/? It covers the balance sheet, income statement, cash flow and Equlion model projections.